Plus Therapeutics Inc
PSTV
View Detailed Chart
0.260USD
+0.026+11.12%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
34.20MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+11.12%
5 Days
+13.94%
1 Month
-53.67%
6 Months
-65.79%
Year to Date
-49.27%
1 Year
-79.70%
View Detailed Chart
TradingKey Stock Score of Plus Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Plus Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 115 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.90.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Plus Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Plus Therapeutics Inc Highlights
StrengthsRisks
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 2500.00% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.82M.
Overvalued
The company’s latest PE is -0.33, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.32M shares, increasing 33.79% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.28M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.28.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
5.900
Target Price
+2422.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Plus Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Plus Therapeutics Inc Info
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Ticker SymbolPSTV
CompanyPlus Therapeutics Inc
CEOHedrick (Marc H)
Websitehttp://www.plustherapeutics.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
67745.560
-2224.570 (-3.18%)
282.580
+22.390 (+8.61%)
2008.390
-43.340 (-2.11%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
